ConductScience.org, home

Paper1804005

In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises.

Thomson KS and 2 others. Antimicrob Agents Chemother, 1991. Cited by 30 papers, by iCite.

Cite this record

ConductScience Library. In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises. Papers, record 1804005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1804005

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises.
PubMed
Journal
Antimicrob Agents Chemother
PubMed
Year
1991
PubMed
Publication types
Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
30
iCite
Relative citation ratio, by iCite
1.56
iCite
Revised in PubMed
2021-05-26
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Thomson KSK S
2Sanders CCC C
3Hayden MEM E

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Infective AgentsMajor topic
BacteriaMajor topic
Ciprofloxacin
Drug Resistance, Microbial
Enterobacteriaceae
Microbial Sensitivity Tests
Mutation
Pseudomonas aeruginosa
Staphylococcus

Source PubMed

Download CSV of topics

References13

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
11649574Escherichia coli resistant to cephalosporins and quinolones is still susceptible to the cephalosporin-quinolone ester Ro 23-9424.Antimicrob Agents Chemother1991https://conductscience.org/library/papers/1649574PubMed
21649573Spontaneous quinolone resistance in Serratia marcescens due to a mutation in gyrA.Antimicrob Agents Chemother1991https://conductscience.org/library/papers/1649573PubMed
31827242Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus.Antimicrob Agents Chemother1991https://conductscience.org/library/papers/1827242PubMed
42024969Uptake of sparfloxacin and norfloxacin by clinical isolates of Staphylococcus aureus.Antimicrob Agents Chemother1991https://conductscience.org/library/papers/2024969PubMed
52024958Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center.Antimicrob Agents Chemother1991https://conductscience.org/library/papers/2024958PubMed
62175305The clinical problems of bacterial resistance to the new quinolones.J Antimicrob Chemother1990https://conductscience.org/library/papers/2175305PubMed
72889094Quinolone/ureidopenicillin cross-resistance.Lancet1987https://conductscience.org/library/papers/2889094PubMed
82254224Epidemiology of ciprofloxacin resistance among patients with methicillin-resistant Staphylococcus aureus.J Antimicrob Chemother1990https://conductscience.org/library/papers/2254224PubMed
92690616Bacterial resistance to the quinolone antimicrobial agents.Am J Med1989https://conductscience.org/library/papers/2690616PubMed
102680058Fluoroquinolone antimicrobial agents.Clin Microbiol Rev1989https://conductscience.org/library/papers/2680058PubMed
112679373
Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction.
Antimicrob Agents Chemother1989https://conductscience.org/library/papers/2679373PubMed
122663809Mechanisms of resistance to quinolones and clinical perspectives.J Antimicrob Chemother1989https://conductscience.org/library/papers/2663809PubMed
132086223First clinical isolate of highly fluoroquinolone-resistant Escherichia coli in Scandanavia.Eur J Clin Microbiol Infect Dis1990https://conductscience.org/library/papers/2086223PubMed

Download CSV of references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.

PMIDTitleJournalYearIn PapersSource
30977288lptG contributes to changes in membrane permeability and the emergence of multidrug hypersusceptibility in a cystic fibrosis isolate of Pseudomonas aeruginosa.Microbiologyopen2019https://conductscience.org/library/papers/30977288PubMed
17517839Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.Antimicrob Agents Chemother2007https://conductscience.org/library/papers/17517839PubMed
16251325AmpC and OprD are not involved in the mechanism of imipenem hypersusceptibility among Pseudomonas aeruginosa isolates overexpressing the mexCD-oprJ efflux pump.Antimicrob Agents Chemother2005https://conductscience.org/library/papers/16251325PubMed
12545697The use of antimicrobial peptides in ophthalmology: an experimental study in corneal preservation and the management of bacterial keratitis.Trans Am Ophthalmol Soc2002https://conductscience.org/library/papers/12545697PubMed
10378126Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.Infection1999https://conductscience.org/library/papers/10378126PubMed
9835538Examination of methicillin-resistant and methicillin-susceptible Staphylococcus aureus mutants with low-level fluoroquinolone resistance.Antimicrob Agents Chemother1998https://conductscience.org/library/papers/9835538PubMed
9257770In vitro activity of Bay 12-8039, a new 8-methoxyquinolone.Antimicrob Agents Chemother1997https://conductscience.org/library/papers/9257770PubMed
9098667Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.Drugs1997https://conductscience.org/library/papers/9098667PubMed
8285618In vitro activity of Bay y 3118, a new quinolone.Antimicrob Agents Chemother1993https://conductscience.org/library/papers/8285618PubMed
8118787Update on clinical significance of coagulase-negative staphylococci.Clin Microbiol Rev1994https://conductscience.org/library/papers/8118787PubMed
7840550Antimicrobial susceptibility of coagulase-negative staphylococci.Antimicrob Agents Chemother1994https://conductscience.org/library/papers/7840550PubMed
7811025Dissociated resistance among fluoroquinolones.Antimicrob Agents Chemother1994https://conductscience.org/library/papers/7811025PubMed
7492087Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa.Antimicrob Agents Chemother1995https://conductscience.org/library/papers/7492087PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/1804005

GET https://conductscience.org/api/papers/v1/1804005/authors